Article Information
History
- November 16, 2021.
Article Versions
- Version 1 (November 11, 2021 - 07:56).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Meemansa Sood1,2,*,
- Mohamed Aborageh1,2,
- Daniel Domingo-Fernández1,2,3,
- Robbert Harms4,5,
- Thomas Lordick1,2,
- Colin Birkenbihl1,2,
- Andrew P Owens6,
- Neva Coello7,
- Vaibhav A. Narayan8,
- Dag Aarsland6,
- Maximilian Bügler4,5,
- Holger Fröhlich1,2,*,
- for the Alzheimer’s Disease Neuroimaging Initiative†,
- RADAR-AD Consortium
- 1Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), 53754 Sankt Augustin, Germany
- 2University of Bonn, Bonn-Aachen International Center for IT, Friedrich-Hirzebruch Allee 6, 53115 Bonn, Germany
- 3Enveda Biosciences, Boulder, CO, 80301, USA
- 4Altoida Inc. 2100 West Loop South, Suite 1450, Houston, TX 77027, USA
- 5Altoida AG Hirschengraben 31, 6003, Lucerne, Switzerland
- 6Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
- 7Novartis Pharmaceuticals, Basel, Switzerland
- 8Janssen Neuroscience Research & Development, Titusville, NJ, USA
- ↵*correspondence:meemansa.sood{at}scai.fraunhofer.de, holger.froehlich{at}scai.fraunhofer.de
Posted November 16, 2021.
Evaluating Digital Device Technology in Alzheimer’s Disease via Artificial Intelligence
